2018.Aug.15
OBI received notice from patent attorney’s office that product patent for OBI-3424 named "DNA alkylating agents" has been approved by IP Australia
Date of occurrence of the event: Aug 15, 2018 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: N/A Cause of occurrence: OBI received notice from patent attorney’s office that product patent for OBI-3424 named “DNA alkylating agents” has been approved by IP Australia […]
This article is password protected.
To view the content, please enter your password in the field below